Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710893 | 0.94 | VDR (0.61) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL7716606 | 0.94 | VDR (0.61) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL7716794 | 0.91 | VDR (0.58) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL7715728 | 0.91 | VDR (0.58) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL8995587 | 0.90 | VDR (0.56) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL8995620 | 0.90 | VDR (0.56) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL5376260 | 0.90 | VDR (0.56) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL5376548 | 0.90 | VDR (0.56) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL8995643 | 0.90 | VDR (0.57) | VDRNR1I2PGRHTR1AADORA3 | |
| SCHEMBL8526158 | 0.89 | VDR (0.56) | VDRNR1I2PGRHTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221753-B2 | Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-12-29 | — | — | US | disclosed |
| US-20070135394-A1 | Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135394-A1 | Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds | CYP24A1, CYP2R1, VDR | VDR 3/4885NR1I2 3727/4885PGR 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.